Peritoneal carcinoma in a male patient

Oncology

Volumn 64, Issue 4, 2003, Pages 468-472

  Jermann, Monika ^a   Vogt, Peter ^a   Pestalozzi, Bernhard C ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Immunohistochemistry; Male peritoneal carcinoma

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GEMCITABINE; PACLITAXEL;

ADULT; ARTICLE; ASCITES; AUTOPSY; CANCER CHEMOTHERAPY; CANCER REGRESSION; CARCINOMATOUS PERITONITIS; CASE REPORT; DISEASE COURSE; ELECTRON MICROSCOPY; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; OVARY CANCER; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR BIOPSY; CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; FATALITY; METASTASIS; MIDDLE AGED; PATHOLOGY; PERITONEUM TUMOR; SEROSA;

ASCITES; AUTOPSY; CARCINOMA; DIAGNOSIS, DIFFERENTIAL; FATAL OUTCOME; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PERITONEAL NEOPLASMS; SEROUS MEMBRANE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0038312245     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000070308     Document Type: Article

References (16)

1. Shah IA, Jayram L, Gani OS, Fox IS, Stanley TM: Papillary serous carcinoma of the peritoneum in a man: A case report. Cancer 1998;82:860-866.
2. Chu CS, Menzin AW, Leonard DGB, Tubin SC, Wheeler JE: Primary peritoneal carcinoma: A review of the literature. Obstet Gynecol Surv 1999;54:323-335.
3. Ordonez NG: Role of immunohistochemistry in distinguishing epithelial peritoneal mesothe-liomas from peritoneal and ovarian serous carcinomas. Am J Surg Pathol 1998;22:1203-1214.
4. The Ovarian Cancer Meta-Analysis Project: Cyclophosphamide plus cisplatin versus cyclo-phosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: A meta-analysis. J Clin Oncol 1991;9:1668-1674.
5. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M: Cyclophosphamide and cis-platin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
6. Ozols RF, Bundy BN, Fowler J, Clarke-Pearson D, Mannel R, Hartenbach EM, Baergen R: Randomized phase III study of cisplatin (CIS)/paclitaxel (PAC) versus carboplatin (CARBO)/PAC in optimal stage III epithelial ovarian cancer (OC). Proc ASCO 1999;18:356a.
7. Du Bois A, Lueck HJ, Meier W, Moebus V, Costa SD, Bauknecht T, Richter B, Warm M: Cisplatin/paclitaxel vs. carboplatin/paclitaxel in ovarian cancer: Update of Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Trial. Proc ASCO 1999;18:356a.
8. Harper P on behalf of the ICON Collaborators. Cancer Division MRC Clinical Trials Unit Cambridge UK: A randomised comparison of paclitaxel (T) and carboplatin (J) versus a control arm of single agent carboplatin (J) or CAP (cyclophosphamide, doxorubicin and cisplatin): 275 patients randomised into the 3rd International Collaborative Ovarian Neoplasm Study (ICON3). Proc ASCO 1999;18:356a.
9. Kennedy AW, Markman M, Webster KD, Kulp B, Peterson G, Rybicki LA, Belinson JL: Experience with platinum-paclitaxel chemotherapy in the initial management of papillary serous carcinoma of the peritoneum. Gynecol Oncol 1998;71:288-290.
10. Kaufmann M, von Minckwitz G: Gemcitabine in ovarian cancer: An overview of safety and efficacy. Eur J Cancer 1997;33(suppl 1):S31-S33.
11. Shapiro JD, Millward MJ, Rischin D, Michael M, Walcher V, Francis PA, Toner GC: Activity of gemcitabine in patients with advanced ovarian cancer: Responses seen following platinum and paclitaxel. Gynecol Oncol 1996;63:89-93.
12. Piura B, Meirovitz M, Bartfeld M, Yanai-Inbar I, Cohen Y: Peritoneal papillary serous carcinoma: Study of 15 cases and comparison with stage III-IV ovarian papillary serous carcinoma. J Surg Oncol 1998;68:173-178.
13. Swerdlow M: Mesothelioma of the pelvic peritoneum resembling papillary cystadenocarcinoma of the ovary. Am J Obstet Gnyecol 1959;77:197-200.
14. Stratton JF, Gayther SA, Russell P, Dearden J, Gore M, Blake P, Easton D, Ponder BA: Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med 1997;336:1125-1130.
15. Takahashi H, Behbakht K, McGovern PE, Chiu HC, Couch FJ, Weber B, Friedman LS, King MC, Furusato M, Livolsi VA: Mutation analysis of the BRCA1 gene in ovarian cancers. Cancer Res 1995;55:2998-3002.
16. Bandera CA, Muto MG, Schorge JO, Berkowitz RS, Rubin SC, Mok SC: BRCA1 gene mutations in women with papillary serous carcinoma of the peritoneum. Obstet Gynecol 1998;92:596-600.